Literature DB >> 24727210

Psychostimulants, antidepressants and neurokinin-1 receptor antagonists ('motor disinhibitors') have overlapping, but distinct, effects on monoamine transmission: the involvement of L-type Ca2+ channels and implications for the treatment of ADHD.

S Clare Stanford1.   

Abstract

Both psychostimulants and antidepressants target monoamine transporters and, as a consequence, augment monoamine transmission. These two groups of drugs also increase motor activity in preclinical behavioural screens for antidepressants. Substance P-preferring receptor (NK1R) antagonists similarly increase both motor activity in these tests and monoamine transmission in the brain. In this article, the neurochemical and behavioural responses to these three groups of drugs are compared. It becomes evident that NK1R antagonists represent a distinct class of compounds ('motor disinhibitors') that differ substantially from both psychostimulants and antidepressants, especially during states of heightened arousal or stress. Also, all three groups of drugs influence the activation of voltage-gated Ca(v)1.2 and Ca(v)1.3 L-type channels (LTCCs) in the brain, albeit in different ways. This article discusses evidence that points to disruption of these functional interactions between NK1R and LTCCs as a contributing factor in the cognitive and behavioural abnormalities that are prominent features of Attention Deficit Hyperactivity Disorder (ADHD). Arising from this is the interesting possibility that the hyperactivity and impulsivity (as in ADHD) and psychomotor retardation (as in depression) reflect opposite poles of a behavioural continuum. A better understanding of this pharmacological network could help explain why psychostimulants augment motor behaviour during stress (e.g., in preclinical screens for antidepressants) and yet reduce locomotor activity and impulsivity in ADHD. This article is part of the Special Issue entitled 'CNS Stimulants'.
Copyright © 2014 The Author. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Antidepressant; Attention Deficit Hyperactivity Disorder (ADHD); L-type calcium channel (LTCC); Monoamine transmission; Neurokinin receptor (NK1R) antagonist; Nifedipine; Psychostimulant

Mesh:

Substances:

Year:  2014        PMID: 24727210     DOI: 10.1016/j.neuropharm.2014.03.021

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  9 in total

1.  The effect of hypocalcemia in early childhood on autism-related social and communication skills in patients with 22q11 deletion syndrome.

Authors:  Meghan Muldoon; Opal Y Ousley; Lisa J Kobrynski; Sheena Patel; Matthew E Oster; Samuel Fernandez-Carriba; Joseph F Cubells; Karlene Coleman; Bradley D Pearce
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-09-30       Impact factor: 5.270

2.  Animal Models of ADHD?

Authors:  S Clare Stanford
Journal:  Curr Top Behav Neurosci       Date:  2022

3.  The angiotensin converting enzyme inhibitor, captopril, prevents the hyperactivity and impulsivity of neurokinin-1 receptor gene 'knockout' mice: sex differences and implications for the treatment of attention deficit hyperactivity disorder.

Authors:  Ashley J Porter; Katharine Pillidge; Ewelina M Grabowska; S Clare Stanford
Journal:  Eur Neuropsychopharmacol       Date:  2015-02-07       Impact factor: 4.600

4.  Atomoxetine reduces hyperactive/impulsive behaviours in neurokinin-1 receptor 'knockout' mice.

Authors:  Katharine Pillidge; Ashley J Porter; Temis Vasili; David J Heal; S Clare Stanford
Journal:  Pharmacol Biochem Behav       Date:  2014-10-24       Impact factor: 3.533

5.  Differences in the performance of NK1R-/- ('knockout') and wildtype mice in the 5‑Choice Continuous Performance Test.

Authors:  Ashley J Porter; Katharine Pillidge; S Clare Stanford; Jared W Young
Journal:  Behav Brain Res       Date:  2015-11-11       Impact factor: 3.332

6.  The behavioural response of mice lacking NK₁ receptors to guanfacine resembles its clinical profile in treatment of ADHD.

Authors:  Katharine Pillidge; Ashley J Porter; Julia A Dudley; Yuan-Chen Tsai; David J Heal; S Clare Stanford
Journal:  Br J Pharmacol       Date:  2014-10       Impact factor: 8.739

7.  The NK1R-/- mouse phenotype suggests that small body size, with a sex- and diet-dependent excess in body mass and fat, are physical biomarkers for a human endophenotype with vulnerability to attention deficit hyperactivity disorder.

Authors:  Katharine Pillidge; David J Heal; S Clare Stanford
Journal:  J Psychopharmacol       Date:  2016-07-26       Impact factor: 4.153

8.  An integrative approach to investigate the respective roles of single-nucleotide variants and copy-number variants in Attention-Deficit/Hyperactivity Disorder.

Authors:  Leandro de Araújo Lima; Ana Cecília Feio-dos-Santos; Sintia Iole Belangero; Ary Gadelha; Rodrigo Affonseca Bressan; Giovanni Abrahão Salum; Pedro Mario Pan; Tais Silveira Moriyama; Ana Soledade Graeff-Martins; Ana Carina Tamanaha; Pedro Alvarenga; Fernanda Valle Krieger; Bacy Fleitlich-Bilyk; Andrea Parolin Jackowski; Elisa Brietzke; João Ricardo Sato; Guilherme Vanoni Polanczyk; Jair de Jesus Mari; Gisele Gus Manfro; Maria Conceição do Rosário; Eurípedes Constantino Miguel; Renato David Puga; Ana Carolina Tahira; Viviane Neri Souza; Thais Chile; Gisele Rodrigues Gouveia; Sérgio Nery Simões; Xiao Chang; Renata Pellegrino; Lifeng Tian; Joseph T Glessner; Ronaldo Fumio Hashimoto; Luis Augusto Rohde; Patrick M A Sleiman; Hakon Hakonarson; Helena Brentani
Journal:  Sci Rep       Date:  2016-03-07       Impact factor: 4.379

9.  Whole exome sequencing in ADHD trios from single and multi-incident families implicates new candidate genes and highlights polygenic transmission.

Authors:  Bashayer R Al-Mubarak; Aisha Omar; Batoul Baz; Basma Al-Abdulaziz; Amna I Magrashi; Eman Al-Yemni; Amjad Jabaan; Dorota Monies; Mohamed Abouelhoda; Dejene Abebe; Mohammad Ghaziuddin; Nada A Al-Tassan
Journal:  Eur J Hum Genet       Date:  2020-04-01       Impact factor: 5.351

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.